Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | GSK3B | P49841 | 2/20 | 0.48 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
| ▸ | FLT4 | P35916 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4046791 | 0.98 | ALDH1A1 (0.65) | ALDH1A1MAPK1HIF1AABL1GSK3B | |
| SCHEMBL2450666 | 0.85 | ALDH1A1 (0.61) | ALDH1A1MAPK1HIF1AABL1GSK3B | |
| SCHEMBL30249612 | 0.83 | ABL1 (0.59) | ALDH1A1MAPK1HIF1AABL1FLT1 | |
| SCHEMBL8129402 | 0.83 | ABL1 (0.54) | ALDH1A1MAPK1HIF1AABL1GSK3B | |
| SCHEMBL9041985 | 0.83 | ABL1 (0.59) | ALDH1A1MAPK1HIF1AABL1FLT1 | |
| SCHEMBL5636998 | 0.82 | ABL1 (0.50) | ALDH1A1MAPK1HIF1AABL1FLT1 | |
| SCHEMBL20447579 | 0.81 | GSK3B (0.48) | ALDH1A1MAPK1HIF1AGSK3BKDM4E | |
| SCHEMBL18637905 | 0.80 | ABL1 (0.51) | ALDH1A1MAPK1HIF1AABL1FLT1 | |
| SCHEMBL7447640 | 0.80 | ABL1 (0.56) | ALDH1A1MAPK1HIF1AABL1FLT1 | |
| SCHEMBL27439105 | 0.80 | ABL1 (0.51) | ALDH1A1MAPK1HIF1AABL1FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970097-B1 | METHODS FOR THE SYNTHESIS OF CHIRAL KYNURENINE COMPOUNDS | VISTAGEN THERAPEUTICS INC (US) | 2018-10-31 | — | — | EP | claimed |
| US-9834801-B2 | Methods for the synthesis of chiral kynurenine compounds | VISTAGEN THERAPEUTICS, INC. (US) | 2017-12-05 | — | — | US | claimed |
| US-20160032334-A1 | METHODS FOR THE SYNTHESIS OF CHIRAL KYNURENINE COMPOUNDS | VISTAGEN THERAPEUTICS, INC. | 2016-02-04 | — | — | US | claimed |
| EP-2970097-A1 | METHODS FOR THE SYNTHESIS OF CHIRAL KYNURENINE COMPOUNDS | Vistagen Therapeutics, Inc. (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2014152752-A1 | METHODS FOR THE SYNTHESIS OF CHIRAL KYNURENINE COMPOUNDS | VISTAGEN THERAPEUTICS, INC. (US) | 2014-09-25 | — | — | WO | claimed |
| CN-116891484-A | Condensed ring compound, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2023-10-17 | — | — | CN | disclosed |
| US-10294502-B2 | Methods for the synthesis of chiral kynurenine compounds | VISTAGEN THERAPEUTICS, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-10294502-B2 | Methods for the synthesis of chiral kynurenine compounds | VISTAGEN THERAPEUTICS, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| EP-2970097-B1 | METHODS FOR THE SYNTHESIS OF CHIRAL KYNURENINE COMPOUNDS | VISTAGEN THERAPEUTICS INC (US) | 2018-10-31 | — | — | EP | disclosed |
| US-20180305298-A1 | DEUTERATED CHLOROKYNURENINES FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | CEPHALON, INC. | 2018-10-25 | — | — | US | disclosed |
| EP-3362423-A1 | DEUTERATED CHLOROKYNURENINES FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | Auspex Pharmaceuticals, Inc. (US) | 2018-08-22 | — | — | EP | disclosed |
| US-20180171372-A1 | METHODS FOR THE SYNTHESIS OF CHIRAL KYNURENINE COMPOUNDS | VISTAGEN THERAPEUTICS, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| EP-1503998-B1 | HETEROARYL SUBSTITUTED SPIROCYCLIC SUFAMIDES FOR INHIBITION OF GAMMA SECRETASE | MERCK SHARP & DOHME (GB) | 2009-07-01 | — | — | EP | disclosed |
| US-20080070895-A1 | Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase | COLLINS IAN J | 2008-03-20 | — | — | US | disclosed |
| US-7282513-B2 | Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase | MERCK SHARP & DOHME LIMITED (GB) | 2007-10-16 | — | — | US | disclosed |
| US-20060173054-A1 | Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2006-08-03 | — | — | US | disclosed |
| US-7041689-B2 | Heteroaryl substituted spriocyclic sulfamides for inhibition of gamma secretase | MERCK SHARP & DOHME LTD. (GB) | 2006-05-09 | — | — | US | disclosed |
| US-20050182109-A1 | Heteroaryl substituted spriocyclic sulfamides for inhibition of gamma secretase | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2005-08-18 | — | — | US | disclosed |
| EP-1503998-A1 | HETEROARYL SUBSTITUTED SPIROCYCLIC SUFAMIDES FOR INHIBITION OF GAMMA SECRETASE | MERCK SHARP & DOHME LTD. (GB) | 2005-02-09 | — | — | EP | disclosed |
| WO-2003093252-A1 | HETEROARYL SUBSTITUTED SPIROCYCLIC SULFAMIDES FOR INHIBITION OF GAMMA SECRETASE | MERCK SHARP & DOHME LIMITED (GB) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182109-A1 | Heteroaryl substituted spriocyclic sulfamides for inhibition of gamma secretase | BACE1, BACE2, PSEN1 | ALDH1A1 2941/4885MAPK1 3820/4885HIF1A 3673/4885 |
| US-20180305298-A1 | DEUTERATED CHLOROKYNURENINES FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | GRIK3, GRIK1, GRIK2 | ALDH1A1 3248/4885MAPK1 3595/4885HIF1A 2150/4885 |
| US-20180171372-A1 | METHODS FOR THE SYNTHESIS OF CHIRAL KYNURENINE COMPOUNDS | KYNU, KMO, AADAT | ALDH1A1 2822/4885MAPK1 2237/4885HIF1A 3209/4885 |
| US-20060173054-A1 | Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase | BACE1, BACE2, PSEN1 | ALDH1A1 2492/4885MAPK1 3911/4885HIF1A 4013/4885 |
| US-10294502-B2 | Methods for the synthesis of chiral kynurenine compounds | KYNU, KMO, AADAT | ALDH1A1 2822/4885MAPK1 2237/4885HIF1A 3209/4885 |
| US-20080070895-A1 | Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase | BACE1, BACE2, PSEN1 | ALDH1A1 2492/4885MAPK1 3911/4885HIF1A 4013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.